Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Philip Hublitz

Dr. rer. nat.


Head of WIMM Genome Engineering

Genome Engineering Services at WIMM

The MRC WIMM Genome Engineering Facility is a central core service to establish genetically modified model systems. We are available to all researchers in MRC WIMM units as well as to other departments of the University of Oxford. Our team can advise on potential experimental strategies, provide validated reagents and assemble custom repair and targeting donors. We generate custom cell lines by CRISPR/Cas9 gene editing and, in collaboration with the MRC WIMM Transgenic Facility, we generate custom mouse models using our Cas9-assisted mESC targeting pipeline. We also provide expertise in CRISPR screening and virus production in close collaboration with the MRC WIMM Virus and Screening Facility. Please feel free to contact us at any time to find out how we can help.

Biography

2003: Dr. rer. nat. from the Albert Ludwigs University of Freiburg, Germany. Functional studies of transcriptional co-repressors, characterisation of the novel INHAT repressor NIR.

2005 - 2008: Postdoctoral fellowship at the Friedrich Miescher Institute for Biomedical Research in Basel, Switzerland. Research on the function of histone methyltransferases in early mouse development. 

2008 - 2014: Head of the Gene Expression Services at the EMBL Rome outstation. Responsible for the generation of classical and BAC transgenic constructs. Responsible for generation of custom targeting constructs (KO, cKO, KI, cKI). In those pre-CRISPR days, most of the work was done by advanced recombineering and classic HDR techniques.

2014 – today: Head of the MRC WIMM Genome Engineering Facility. Generation of cell and mouse model systems. The rapid development of the CRISPR/Cas9 platform made cell line engineering a fundamental new part of the work.  Besides the assembly of plasmid constructs, the GE core facility offers a wide portfolio of services: KO, KI, cKO, cKI, COIN alleles, SNP modelling, Base Editing, Prime Editing, CRISPRi/a approaches and custom viral screening